Rev Neurol France
-
Multicenter Study Clinical Trial Observational Study
Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
Knowledge of which factors are determinant of quality of life (QoL) in patients with multiple scleroris (MS) would assist clinicians in choosing the most appropriate interventions. The aim of this study was to determine the contribution of sociodemographic and clinical factors in the predicting QoL in a 2-year cohort of patients with relapsing-remitting MS (RR-MS). ⋯ After adjusting for disability and relapse occurrence, sociodemographics (age, marital status, and occupational status) and baseline QoL scores were also independent QoL predictors in MS patients. Special attention should be given to subgroups to ensure optimal management.
-
Multicenter Study Clinical Trial
[The impact of early cranioplasty on cerebral blood flow and its correlation with neurological and cognitive outcome. Prospective multi-centre study on 24 patients].
Cranioplasty after decompressive craniectomy in patients suffering from severe head injury often leads to a functional improvement although, to date, the pathophysiology of this phenomenon remains unclear. A few hypotheses have been proposed. The impact of cranioplasty on cerebral perfusion could be one explanation. We have evaluated the impact of cranioplasty on the functional status of patients undergoing decompressive craniectomy for severe head injury with its influence on cerebral perfusion. ⋯ Cranioplasty after decompressive craniectomy for patients suffering from severe head injury probably improves the functional outcome of these patients, thanks to a global improvement of cerebral perfusion.
-
Randomized Controlled Trial Multicenter Study
[The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an INTEnsive blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT2): protocol and baseline characteristics of patients included in France].
The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure (BP) lowering, and effects on hematoma expansion within 6hours of onset of intracerebral hemorrhage (ICH). This article describes the design of the second, main phase, INTERACT2. INTERACT2 aims to compare the effects of a management strategy of early intensive BP lowering with a more conservative guideline-based BP management policy in patients with acute ICH. This article also compares the baseline characteristics of the patients included in France with the baseline characteristics of the patients included in the pilot study INTERACT1. ⋯ As of early July, 152 patients have been included in France. When compared with the patients randomised in the INTERACT1 pilot study, these patients are older, less likely to have had a previous ICH, more often on antiplatelet or warfarin therapy, have a lower diastolic BP, arere more severe clinically (higher NIHSS) and experience their first ICH.
-
Multicenter Study Clinical Trial
[Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
The primary objective of this prospective, open, non controlled, multicenter study was to collect data on migraine patients' health related quality of life before and after treatment of their migraine attacks by sumatriptan nasal spray 20 mg over a 12 week period. The impact on health related quality of life was evaluated by the mean change from pre-treatment scores french migraine health related quality of life specific questionnaire (QVM). A total of 219 patients have been included in the study, whose migraine attacks were not usually relieved by first line therapy. A statistically significant improvement in health related quality of life (as measured by the global score and the four scores related to the four dimensions of the QVM questionnaire (functional, psychological, social and therapeutic) were observed compared to the pre-treatment score values. At the end of the treatment period, 60% of patients preferred sumatriptan nasal spray 20 mg to their usual treatment. Headache relief was reported 2 hours after administration in 66% of attacks treated by sumatriptan nasal spray 20 mg during the study period and pain free in 46% of treated attacks. The nature and incidence of adverse events were similar to these observed in previous studies performed with sumatriptan nasal spray 20 mg and no unexpected events were reported. ⋯ Those data suggest for the first time that the use of sumatriptan nasal spray 20 mg for the treatment of migraine attacks during a 12 week period may be associated with a significant improvement in migraine patients' quality of life. The clinical efficacy and tolerability results observed in this study are similar to those from controlled studies previously published with sumatriptan nasal spray 20 mg.